Astellas Pharma (OTCMKTS:ALPMY) Posts Quarterly Earnings Results

Astellas Pharma (OTCMKTS:ALPMY) issued its earnings results on Thursday. The company reported $0.11 EPS for the quarter, reports. Astellas Pharma had a return on equity of 5.85% and a net margin of 1.20%. The company had revenue of $2.79 billion during the quarter.

Astellas Pharma Stock Performance

ALPMY opened at $9.55 on Friday. The business has a fifty day simple moving average of $10.53 and a 200 day simple moving average of $11.45. The company has a market capitalization of $17.28 billion, a PE ratio of 27.26, a price-to-earnings-growth ratio of 1.65 and a beta of 0.32. Astellas Pharma has a 1 year low of $9.15 and a 1 year high of $16.91. The company has a debt-to-equity ratio of 0.31, a current ratio of 0.91 and a quick ratio of 0.71.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.